12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Exosomes with low miR-34c-3p expression promote invasion and migration of non-small cell lung cancer by upregulating integrin α2β1

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Exosomes play critical roles in regulating various physiological and pathological processes, including immune stimulation, immune suppression, cardiovascular diseases, and cancers. Recent studies show that exosomes that transport specific microRNAs (miRNAs) are involved in tumor development. However, the molecular mechanism by which tumor invasion and migration are regulated by exosomes from non-small cell lung cancer (NSCLC) is not well understood. Here, we show that exosomes shuttling low levels of miR-34c-3p are involved in NSCLC progression. Our results showed that exosomes derived from NSCLC cells carrying low levels of miR-34c-3p could be transported into the cytoplasm of NSCLC cells and accelerate NSCLC invasion and migration by upregulating integrin α2β1. A luciferase assay revealed that integrin α2β1 was the direct target of miR-34c-3p, and overexpression of integrin α2β1 could promote the invasion and migration of NSCLC cells. The analysis of exosomes derived from clinical serum samples indicated that the expression of miR-34c-3p was significantly downregulated in exosomes from NSCLC patients compared with that of normal controls. A549-derived exosomes promoted NSCLC cells lung metastases in vivo. Exosomes shuttling low levels of miR-34c-3p were associated with the progression of NSCLC in vitro and in vivo. Our data demonstrate that exosomes shuttling low levels of miR-34c-3p can accelerate the invasion and migration of NSCLC by upregulating integrin α2β1. MiR-34c-3p can be a diagnostic and prognostic marker for NSCLC. High expression of integrin α2β1 is positively related to the migration and metastasis of NSCLC cells.

          Related collections

          Most cited references29

          • Record: found
          • Abstract: found
          • Article: not found

          Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis.

          Exosomes are naturally occurring biological nanovesicles utilized by tumors to communicate signals to local and remote cells and tissues. Melanoma exosomes can incite a proangiogenic signaling program capable of remodeling tissue matrices. In this study, we show exosome-mediated conditioning of lymph nodes and define microanatomic responses that license metastasis of melanoma cells. Homing of melanoma exosomes to sentinel lymph nodes imposes synchronized molecular signals that effect melanoma cell recruitment, extracellular matrix deposition, and vascular proliferation in the lymph nodes. Our findings highlight the pathophysiologic role and mechanisms of an exosome-mediated process of microanatomic niche preparation that facilitates lymphatic metastasis by cancer cells.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Revisions in the International System for Staging Lung Cancer.

            Revisions in stage grouping of the TNM subsets (T=primary tumor, N=regional lymph nodes, M=distant metastasis) in the International System for Staging Lung Cancer have been adopted by the American Joint Committee on Cancer and the Union Internationale Contre le Cancer. These revisions were made to provide greater specificity for identifying patient groups with similar prognoses and treatment options with the least disruption of the present classification: T1N0M0, stage IA; T2N0M0, stage IB; T1N1M0, stage IIA; T2N1M0 and T3N0M0, stage IIB; and T3N1M0, T1N2M0, T2N2M0, T3N2M0, stage IIIA. The TNM subsets in stage IIIB-T4 any N M0, any T N3M0, and in stage IV-any T any N M1, remain the same. Analysis of a collected database representing all clinical, surgical-pathologic, and follow-up information for 5,319 patients treated for primary lung cancer confirmed the validity of the TNM and stage grouping classification schema.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer

              Background: Functional microRNAs (miRNAs) in exosomes have been recognised as potential stable biomarkers in cancers. The aim of this study is to identify specific miRNAs in exosome as serum biomarkers for the early detection of recurrence in human colorectal cancer (CRC). Methods: Serum samples were sequentially obtained from six patients with and without recurrent CRC. The miRNAs were purified from exosomes, and miRNA microarray analysis was performed. The miRNA expression profiles and copy number aberrations were explored using microarray and array CGH analyses in 124 CRC tissues. Then, we validated exosomal miRNAs in 2 serum sample sets (90 and 209 CRC patients) by quantitative real-time RT–PCR. Results: Exosomal miR-17-92a cluster expression level in serum was correlated with the recurrence of CRC. Exosomal miR-19a expression levels in serum were significantly increased in patients with CRC as compared with healthy individuals with gene amplification. The CRC patients with high exosomal miR-19a expression showed poorer prognoses than the low expression group (P<0.001). Conclusions: Abundant expression of exosomal miR-19a in serum was identified as a prognostic biomarker for recurrence in CRC patients.
                Bookmark

                Author and article information

                Contributors
                jianyez@163.com
                Journal
                Signal Transduct Target Ther
                Signal Transduct Target Ther
                Signal Transduction and Targeted Therapy
                Nature Publishing Group UK (London )
                2095-9907
                2059-3635
                22 April 2020
                22 April 2020
                2020
                : 5
                : 39
                Affiliations
                [1 ]ISNI 0000 0000 8653 1072, GRID grid.410737.6, Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, , Guangzhou Medical University, ; 511436 Guangzhou, Guangdong P.R. China
                [2 ]ISNI 0000 0004 1757 5302, GRID grid.440639.c, Institute of Respiratory and Occupational Diseases, Collaborative Innovation Center for Cancer, Medical College, , Shanxi Datong University, ; 037009 Datong, P.R. China
                [3 ]ISNI 0000 0004 1764 5980, GRID grid.221309.b, School of Chinese Medicine, , Hong Kong Baptist University, ; Hong Kong, P.R. China
                [4 ]ISNI 0000 0000 8653 1072, GRID grid.410737.6, College of Public Health, , Guangzhou Medical University, ; 511436 Guangzhou, Guangdong P.R. China
                [5 ]Cancer Center of Datong, the Second People’s Hospital of Datong, 037005 Shanxi, P.R. China
                [6 ]ISNI 0000 0000 8653 1072, GRID grid.410737.6, GZMU-GIBH School of Life Sciences, , Guangzhou Medical University, ; 511436 Guangzhou, Guangdong P.R. China
                [7 ]GRID grid.464473.6, Xinjiang Institute of Materia Medica, ; 830004 Urumqi, P.R. China
                [8 ]GRID grid.464423.3, Department of Pathology, , Shanxi Provincial People’s Hospital, ; 030012 Taiyuan, P.R. China
                [9 ]ISNI 0000 0004 0368 7493, GRID grid.443397.e, Key Laboratory of Tropical Translational Medicine of Ministry of Education, , Hainan Medical University, ; 571199 Haikou, P.R. China
                Author information
                http://orcid.org/0000-0001-5242-3687
                Article
                133
                10.1038/s41392-020-0133-y
                7174429
                32317629
                755c3a61-45d8-4ede-856a-107a4eae108e
                © The Author(s) 2020

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 8 May 2019
                : 15 January 2020
                : 10 February 2020
                Funding
                Funded by: FundRef https://doi.org/10.13039/501100001809, National Natural Science Foundation of China (National Science Foundation of China);
                Award ID: 81773888
                Award Recipient :
                Categories
                Article
                Custom metadata
                © The Author(s) 2020

                tumour biomarkers,lung cancer
                tumour biomarkers, lung cancer

                Comments

                Comment on this article